Clinical trials: Human Immunodeficiency Virus Type 1
HIV-1 Infection
Compare the Efficacy and Safety of Raltegravir Versus Efavirenz Combination Therapy in Treatment-naïve HIV-1 Patients
A pilot study to compare the efficacy and safety of raltegravir-based versus efavirenz-based combination therapy in treatment-naïve patients with HIV-1 infection.
- Trial name
- NCT01989910
- Testing
- Raltegravir, Efavirenz
- Where
- Taiwan
- Volunteers
- 107 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
HIV-1 Infection
Capacity of the Dual Combination Raltegravir/Etravirine to Maintain Virological Success in HIV-1 Infected Patients of at Least 45 Years of Age- ANRS 163 ETRAL
This multicenter, international, non randomized (single arm), open, phase II trial aims to evaluate the capacity of the dual combination raltegravir/etravirine to maintain virological success in virologically suppressed HIV-1…
- Trial name
- NCT02212379
- Testing
- raltegravir and etravirine
- Where
- 19 sites in France, Spain
- Volunteers
- 170 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV Infections
Effectiveness and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) in HIV Patients Who Have Never Received Treatment
The purpose of this study is to see how effective and safe it is to give 1 of the 3 following treatments to patients who may not have received anti-HIV treatment: 1) lamivudine (3TC)/abacavir (ABC)/stavudine (d4T); 2)…
- Trial name
- NCT00005017
- Testing
- Ritonavir, Abacavir sulfate, Amprenavir
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Glaxo Wellcome
HIV Infections
A Phase I Trial of Intranasal Peptide T: Safety, Toxicity, and Pharmacokinetics in Human Immunodeficiency Virus-1 (HIV-1) Infected Patients.
To study the safety and toxicity of intranasal peptide T (D-Ala-1-peptide-T-amide) in humans, and to find out how quickly and how much of a given dose enters the bloodstream and how quickly it leaves the bloodstream.
- Trial name
- NCT00000391
- Testing
- Peptide T
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Mental Health (NIMH)
HIV-1 Infection, Pf Subclinical Parasitemia
Comparing PI-Based to a nNRTI-based ART for Clearance of Plasmodium Falciparum Parasitemia in HIV-Infected
The purpose of this study was to see if antiretroviral therapy (ART) is safe and works at getting rid of malaria in blood and to see whether one type of ART is better than another.
- Trial name
- NCT01632891
- Testing
- Lopinavir/ritonavir, Emtricitabine/tenofovir disoproxil fumarate, Efavirenz
- Where
- 5 sites in Kenya, Malawi and 1 more
- Volunteers
- 52 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
HIV-1-infection, Cancer
Coronavirus (COVID-19) Outcomes Registries in Immunocompromised Individuals Australia (CORIA)
CORIA is an observational cohort study of immunosuppressed populations who test positive for COVID-19. This includes people living with HIV, cancer, acquired immunodeficiency associated with other immunosuppressive therapy…
- Conditions
- HIV-1-infection, Cancer, Primary Immune Deficiency Disorder, Immunosuppression Disorders
- Trial name
- CORIA (NCT04354818)
- Where
- 11 sites in Australia
- Volunteers
- 27 people
- Sponsor
- Kirby Institute
HIV Infections, Neurologic Disorders
Anakinra, A Recombinant Human IL-1 Receptor Antagonist for Neuroinflammation in HIV-1 Infection
Background: HIV can sometimes cause HIV-associated neurocognitive disorder, or HAND. HAND is HIV-associated neurocognitive disorder. It can affect memory, thinking, or concentration. It can cause mood changes.
- Trial name
- NCT02527460
- Testing
- Anakinra
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
HIV Infections
Comparison of Three Different Initial Treatments Without Protease Inhibitors for HIV Infection
The purpose of this study is to compare the effectiveness, safety, and tolerability of 3 anti-HIV combination treatments that do not use protease inhibitors (PIs).
- Trial name
- NCT00013520
- Testing
- Abacavir sulfate, Lamivudine and Zidovudine, Atazanavir, Lamivudine/Zidovudine
- Where
- 60 sites in United States, Puerto Rico
- Volunteers
- 1,125 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1 Infection
Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)
This is a phase 3, randomized, controlled, double-blind, multisite clinical study of a once-daily fixed dose combination (FDC) of 100 mg doravirine/0.75 mg islatravir (DOR/ISL [also known as MK-8591A]) in treatment-naïve…
- Trial name
- NCT04233879
- Testing
- DOR/ISL, BIC/FTC/TAF
- Where
- 95 sites in United States, Argentina and 11 more
- Volunteers
- 599 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
Once-daily Antiretroviral Therapy in HIV-1 Infected Patients With CD4+ Cell Counts Below 100 Cells/Mcl
There are few randomized clinical trials in advanced HIV patients. This is a multicenter, randomized, open clinical trial, comparing three parallel groups, to compare the immunological reconstitution and the virological efficacy…
- Trial name
- ADVANZ-3 (NCT00532168)
- Testing
- tenofovir + emtricitabine + efavirenz, tenofovir + emtricitabine + lopinavir-ritonavir, tenofovir + emtricitabine + atazanavir-ritonavir
- Where
- Spain
- Volunteers
- 108 people
- Sponsor
- Juan A. Arnaiz
HIV Infections
Neurocognitive Impairment and Psychiatric Comorbidities in HIV-1
To assess the prevalence and risk factors of neurocognitive impairment and psychiatric comorbidities in HIV infected patients who have undetectable viral load, have been on HAART for at least 1 year and have no history of CNS…
- Trial name
- NCT00476671
- Testing
- lumbar puncture, MRI, MRS
- Where
- Thailand
- Volunteers
- 100 people
- Sponsor
- The HIV Netherlands Australia Thailand Research Collaboration
HIV Infections
Safety of and Immune System Response to an HIV Vaccine (EP HIV-1090) in HIV Uninfected Adults
The purpose of this study is to test the safety of an HIV DNA vaccine (EP HIV-1090) and to test whether or not the vaccine can stimulate immune system responses in HIV uninfected people.
- Trial name
- NCT00054860
- Testing
- EP HIV-1090
- Where
- 5 sites in United States, Botswana
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1 Infection
Analytical Treatment Interruption in HIV Positive Patients
HIV-1 infected patients with normal peripheral blood CD4+ T-cell counts and undetectable viral load will be recruited in four Belgian HIV reference centers.
- Trial name
- ISALA (NCT02590354)
- Testing
- ART interruption
- Where
- 4 sites in Belgium
- Volunteers
- 114 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children
The primary objectives of Cohort 1 are to evaluate the steady state pharmacokinetics (PK) for elvitegravir (EVG) and tenofovir alafenamide (TAF) and confirm the dose of the elvitegravir/cobicistat/emtricitabine/tenofovir…
- Trial name
- NCT01854775
- Testing
- E/C/F/TAF, E/C/F/TAF (Low Dose)
- Where
- 16 sites in United States, South Africa and 3 more
- Volunteers
- 129 people
- Sponsor
- Gilead Sciences
HIV Infections
Efficacy and Tolerance of the Switch From Enfuvirtine to Raltegravir in Antiretroviral Therapy Regimen in HIV Patients With Undetectable Viral Load
Switching from enfuvirtide to raltegravir in the treatment of HIV-infected patients who sustain viral suppression with a combination therapy including enfuvirtide (or : with an enfuvirtide-based combination therapy)
- Trial name
- EASIER (NCT00454337)
- Testing
- FTC/TDF + EFV or LPV/R +T20, FTC/TDF + EFV or LPV/R
- Where
- France
- Volunteers
- 170 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
HIV-1-infection
Postpartum Pre-exposure Prophylaxis (PrEP) Study to Evaluate an Adherence Promotion Package for Postpartum Women on PrEP
The postpartum PrEP study (PPS) seeks to evaluate how best to improve adherence to PrEP in postpartum women and to evaluate how acceptable it is to offer HIV self tests for the participant and partner, and provide enhanced…
- Trial name
- PPS (NCT04897737)
- Testing
- HIVST and enhanced adherence biofeedback, Orasure/UrSure test
- Where
- South Africa
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
HIV-1 Infection
Gut-Associated Lymphocyte Trafficking
The gut immune barrier is not fully restored in HIV-1-infected subjects despite they were receiving antiretroviral treatment. This leaky gut leads to microbial translocation from the gut lumen into the bloodstream that fuels…
- Trial name
- GALT (NCT02906137)
- Testing
- Peripheral blood and intestinal biopsies will be collected
- Where
- 2 sites in France
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
Healthy
Vaccine Treatment for HIV-Infection
This study will determine the safety and side effects of an experimental adenoviral vector vaccine given to patients who previously received a different HIV vaccine (VRC-HIVDNA016-00-VP) in a prior NIAID study.
- Trial name
- NCT00108654
- Testing
- VRC-HIVADV014-00-VP
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV -1 Infection
A Clinical Trial Investigating the Safety and Biological Activity of the Antibody BNT351 in Adults Living Without and With HIV
This study will test the safety and blood levels of the antibody BNT351 in people living without and with human immunodeficiency virus (HIV).
- Trial name
- NCT07392372
- Testing
- BNT351
- Where
- 6 sites in United States, Germany
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
HIV Infections
R5 Integrase Study in HIV-1 Naive Patients
This is a pilot, open-label study of raltegravir and maraviroc in combination for the treatment of antiretroviral naïve patients.
- Trial name
- NCT01204905
- Testing
- Raltegravir and Maraviroc in combination
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Maryland, Baltimore
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.